ESC 365 - Insights into the cardiovascular and kidney benefits of MR antagonism: Insights from theFIGARO-DKD and FIDELIO-DKD trials.

Open Access

Insights into the cardiovascular and kidney benefits of MR antagonism: Insights from theFIGARO-DKD and FIDELIO-DKD trials.

Session: Exploring the cardiorenal benefits of MR antagonism in CKD and T2D

Topic: Chronic Kidney Disease

Speaker: Professor G. Filippatos (Athens, GR)

Sponsored by Bayer AG

Event: ESC Congress 2021 - The Digital Experience

Congress Presentation

Add to my library

About the speaker

Professor Gerasimos Filippatos

National & Kapodistrian University of Athens Medical School, Athens (Greece)

77 presentations

11 followers

4 more presentations in this session

Welcome and introductions.

Speaker: Professor S. Anker (Berlin, DE)

How to improve cardiorenal outcomes in patients with CKD and T2D?

Speaker: Doctor M. Senni (Bergamo, IT)

Live Q&A.

Summary and close.

Speaker: Professor S. Anker (Berlin, DE)

Access the full session

Exploring the cardiorenal benefits of MR antagonism in CKD and T2D

Speakers: Professor G. Filippatos, Professor S. Anker, Doctor M. Senni, Professor S. Anker

About the event

ESC Congress 2021 - The Digital Experience

27 August - 30 August 2021

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources